Inspira™ Technologies Reveals Next Generation Liby™ System, an Extracorporeal Membrane Oxygenation System, Targeting a $531 Million Global ECMO Market – Yahoo Finance
RA’ANANA, Israel, July 11, 2022 /PRNewswire/ — Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company” or “Inspira Technologies”) introduces today the “Liby™” System, an advanced form of life support better known by the medical industry as extracorporeal membrane oxygenation (ECMO), used to treat patients with life-threatening heart and lung failure. The Liby™ System is intended to target the $531million global ECMO market. The Inspira Technologies Liby™ system currently under development, is expected to be submitted to the U.S. Food and Drug Administration (FDA) for approval, during the first half of 2023.
The Inspira Technologies Liby™ system is designed to be a new generation ECMO system, with potential advantages that may improve usability and patient care. The Liby™ system is also expected to be the first system designed for integration with the Company’s recently revealed non-invasive HYLA™ blood sensor technology. The addition of the HYLA to patients treated with the Liby™ system, would potentially allow for the real-time and continuous monitoring of patient condition to alert physicians of immediate signs of changes in a patient’s clinical condition
The Liby™ system includes several Inspira Technologies developed features and capabilities as well as a new approach to medical device designs, including a large touchscreen and novel colorful graphical representation that increases the visibility, scope and functionality of data displayed to the medical staff. With its small footprint and lightweight characteristics, the Liby™ system is being designed with a rapid style aerospace-grade aluminum structure to be both lightweight and highly durable, and will be equipped with long battery life, a contributing factor to making the Liby™ system suitable for patient mobility within hospitals and for transportation of patients to hospitals in ambulances.
Product Launch
The Liby™ system is expected to be submitted to the FDA for approval during the first half of 2023. Subject to FDA approval, the Liby™ system’s expected regulatory pathway is intended to be designated as a Class II 510 (K), meaning it may not require human trials.
Business Model – Recurring Revenue
Similar to the Company’s flagship ART™ system, the Liby™ system is being designed to generate recurring revenues based upon consumable sales of its single-use disposable kit, which is an important part of the system’s unique design, aimed at reducing setup time and associated medical-care costs.
Dagi Ben-Noon, Inspira™ Technologies’ Chief Executive Officer, stated:
“The Liby™ system is intended to target one of three market segments within Inspira Technologies product scope. The Liby™ system is expected to introduce the next generation of ECMO within Intensive Care Units (ICUs), due to its practical advantages, designed to improve durability, patient mobility both within the hospital or via ambulance, and ease of use. I believe that these are important advantages for medical teams within over-crowded ICUs, targeting to improve patient outcomes.”
About ECMO Technology
ECMO systems are designed to directly oxygenate and remove carbon dioxide from a patient’s blood, replacing the entire lung function by circulating all of the patient’s blood (5-7 liters) every minute. As a last resort procedure, it requires the patient to be confined to ICUs and is associated with a high level of medical risks.
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology Company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (ART), designed to rebalance patient oxygen saturation levels. The Company’s ART™ technology potentially allows patients to remain awake during treatment while minimizing the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The Company’s products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses the potential benefits to be derived from the use of the Liby™ system, once developed, the expected timing of FDA submission for approval, that the Liby™ system is expected to be designated as a Class II 510(K), meaning it may not require human trials, and that the Liby™ system is being designed to generate recurring revenues based upon consumable sales of its single use disposable kit. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2021 filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website, www.sec.gov
For more details:
US Investor Relations
Miri Segal,
MS-IR LLC
+917-607-8654
msegal@ms-ir.com
US Public Relations
Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)
Or 407-491-4498
IINN@redchip.com
Copyright © 2018-2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Photo – https://mma.prnewswire.com/media/1856618/Inspira_Liby_System.jpg
Photo – https://mma.prnewswire.com/media/1856620/Liby_system.jpg
Logo – https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/inspira-technologies-reveals-next-generation-liby-ecmo-an-extracorporeal-membrane-oxygenation-system-targeting-a-531-million-global-ecmo-market-301583739.html
SOURCE Inspira Technologies
Related Quotes
Shares of several popular fintech stocks continued to slump today, as investors prepare for the start of earnings season and new data this week that will provide a glimpse into the current state of inflation. Shares of the buy now, pay later (BNPL) company Affirm (NASDAQ: AFRM) traded nearly 9% lower in the final hour of trading. Shares of the artificial intelligence lender Upstart (NASDAQ: UPST) traded roughly 1.4% lower, and shares of the digital bank SoFi (NASDAQ: SOFI) traded nearly 4% lower.
Pliant Therapeutics Inc's (NASDAQ: PLRX) Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF) met its primary and secondary endpoints. The data demonstrated that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile. A pooled analysis of PLN-74809 treated patients showed an 80% reduction in forced vital capacity (FVC) decline at 12 weeks versus placebo. Related: Read Why Pliant Therapeutics Shares Are Soaring To
Tech stocks have been hammered this year, but some strategists think now is looking like the time to take a chance on some of these names.
Yahoo Finance anchors discuss the energy markets as oil prices decline.
Yahoo Finance anchors discuss American Airlines reiterating its earnings outlook for Q2.
As fears of recession and the prospect of more aggressive interest rate rises become the talk of the town, investors are turning to Wall Street experts for guidance, namely Leon Cooperman. Cooperman built his $2.5 billion fortune after founding Omega Advisors, which he now runs as a family office. Cooperman is mostly retired today, but he keeps his fingers on the pulse of the market. And now, he finds that in the midst of weakness, stocks may show the strongest signs of life. Explaining his stan
In this article, we will look at 10 best undervalued automobile stocks to buy now. If you want to skip our detailed analysis of the automobile industry, you can go directly to 5 Best Undervalued Automobile Stocks to Buy Now. According to IBISWorld, the global car and automobile manufacturing industry is worth $2.9 trillion by […]
Longleaf Partners Fund, a Memphis-based fund under Southeastern Asset Management, published its “Longleaf Partners International Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. Longleaf Partners International Fund declined 12.04% in the first quarter, while the MSCI EAFE Index declined 5.91%. New investments have a high hurdle to qualify given […]
In this article, we will be taking a look at 10 dividend stocks with over 7% yield. To skip our detailed analysis of dividend investing, you can go directly to see the 5 Dividend Stocks with Over 7% Yield. With the looming threat of rising interest rates, dividend stocks are becoming the only feasible option for […]
Wednesday's CPI inflation rate data should show a new 40-year high. Here's what it means for Federal Reserve policy.
Iterum Therapeutics plc (NASDAQ: ITRM) has agreed with the FDA under the special protocol assessment (SPA) process on the design, endpoints, and statistical analysis of a Phase 3 trial for oral sulopenem etzadroxil-probenecid for uncomplicated urinary tract infections. The pivotal study under the SPA agreement is designed as a non-inferiority trial comparing oral sulopenem and Augmentin (amoxicillin/clavulanate). Related: Iterum Expects To Start Additional Sulopenem Trial In Urinary Tract Infect
Vivek Paul, BlackRock Investment Institute Head of Portfolio Research, joins Yahoo Finance Live to discuss inflation, volatility, growth, and the outlook for the market.
Wood's flagship Ark Innovation ETF has fallen 54% this year as her technology companies have stumbled.
Elon Musk's attempt to scrap his purchase of Twitter Inc may leave the world's wealthiest person in a stronger financial position than before he unveiled the $44 billion deal, with billions of dollars in cash from selling Tesla shares now sitting in the bank. After Musk on Friday tore up his April 25 agreement to buy the social media platform, with Twitter promising to force him to make good, the two sides face a potentially drawn-out legal battle that could still cost Musk billions of dollars, according to legal experts. Whatever the outcome may be, the Tesla chief executive for now appears to be sitting on around $8.5 billion in cash raised from selling shares of the automaker late in April to finance the Twitter acquisition.
Neal Dingmann, Truist Managing Director of Energy Research, joins Yahoo Finance Live to discuss the energy markets and the outlook for oil prices through the second half of the year.
In this article, we discuss the 10 oil stocks to sell before the recession begins. If you want to skip our analysis of the outlook on the oil prices, go directly to the 5 Oil Stocks to Sell Before Recession Begins. In a report issued by Citigroup earlier in July, analysts Francesco Martoccia and Ed Morse […]
The U.S. is likely entering the first dip of a double-dip recession, writes former Federal Reserve Board Governor Robert Heller.
Analyst Keith Weiss says Microsoft's consumer-facing businesses are likely to slow in a downturn. He remains long-term bullish.
(Bloomberg) — BYD Co. shares sank the most in nearly two years after a stake matching the size of Berkshire Hathaway Inc.’s position in the Chinese electric-car giant appeared in Hong Kong’s clearing system, fueling speculation that Warren Buffett’s company may be selling its holdings.Most Read from BloombergElon’s OutFresh US Inflation Peak to Keep Fed on Aggressive Rate PathBiden Administration to Again Extend the Covid Public-Health Emergency Thirteen ‘Perfect Storms’ That Are Sweeping the W
Will these two oil stocks be great again?